Bioxyne Limited (ASX:BXN) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. Bioxyne and wholly owned subsidiary Breathe Life Sciences manufacture and distribute consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. In Australia, Breathe Life Sciences holds controlled substance licenses to import, export, wholesale and manufacture Schedule 3,4 and 8 poisons (Medicinal cannabis), operating a wholesale distribution model as well as direct to patient supply of prescribed medications via telemedicine platform BLS Clinics. Outside of Australia, the business has manufacturing and distribution centres in Japan, the UK, and Europe, and operates direct to consumer supply of its trademarked Dr Watson® brand.

For more information on Bioxyne, please visit https://bioxyne.com